Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain. CNTX-0290, is a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist that is currently being studied in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions. 

Full story. 

Related Posts

AAPM Member Dr. Barreveld Co-Authors Opioid Article for New England Journal of Medicine

Published On:

How Psychologists Can Help Treat Chronic Pain

Published On:

Largescale Real-World Migraine Study Solidifies Efficacy and Safety of Theranica’s Nerivio® Device

Published On: